|
2011/03/04Akiyama S1, Hamaya K1, Ito Y1, Yasuda H2, Abe M1, Abe H1:
1Kudan Clinic
2Department of Clinical Application, Translational Research Center, Tohoku University
Abstract
Objectives: Tumor-specific cytotoxic T lymphocytes (CTLs) can be efficiently activated in vivo by dendritic cell (DC)-based vaccination.
We've already reported that neither WT-1 nor MUC1 pulsed DC vaccination can elicit strong immune response so as to exhibit
anti-tumor effects.
In the current study, we have evaluated the clinical responses in the patients with advanced gastroenterological carcinoma, who
received DC-based immunotherapy.
Methods: DC-based immunotherapy (DC vaccine alone or DC vaccine plus lymphokine-activated killer cell therapy) has been carried
out in the 59 patients with inoperable gastroenterological carcinoma refractory to standard treatment.
DCs which were generated from CD14+ monocytes from lukapheresis by 6-day cultivation with GM-CSF and IL-4, then were matured
by OK-432 and pulsed with the cancer-associated antigens, such as WT-1, MUC1.Synergistic DCs were administered intradermally
more than 5 times at 14-day intervals.
Results: Of 59 patients, 0 patients showed CR, 12 PR and 13 SD. None of the patient experienced adverse events of grade 2 or
higher during the treatment period. Response ratio was 20.3%, control ratio was 42.4%.
Conclusion: In the current study, it has been strongly suggested that DC vaccine-based immunotherapy might be safe and effective
in the patients with advanced gastroenterological carcinoma refractory to standard treatment.
• 국제저널 통합의료학회(지) vol. 3(1): 12-24, 2011
|
